Clinical Trial Update: Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma

View source ↗

Summary

An early-access named-patient program using Ulocuplumab for relapsed multiple myeloma is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Ulocuplumab (ulocuplumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Multiple Myeloma in Relapse, Multiple Myeloma | Status: NO_LONGER_AVAILABLE